Ghost Tree Capital LLC Has Decreased Immunomedics INC (IMMU) Holding by $13.80 Million

Immunomedics, Inc. (NASDAQ:IMMU) LogoInvestors sentiment increased to 1.86 in 2018 Q2. Its up 0.60, from 1.26 in 2018Q1. It increased, as 20 investors sold IMMU shares while 38 reduced holdings. 43 funds opened positions while 65 raised stakes. 139.30 million shares or 18.50% more from 117.56 million shares in 2018Q1 were reported. Rhenman & Prtnrs Asset invested in 1.1% or 455,330 shares. Employees Retirement Association Of Colorado reported 21,350 shares. Td Asset Mgmt invested in 0.01% or 215,088 shares. Glenmede Na has 0% invested in Immunomedics, Inc. (NASDAQ:IMMU). Jennison Associate Lc reported 2.15 million shares. First Allied Advisory Svcs Inc has invested 0.01% in Immunomedics, Inc. (NASDAQ:IMMU). 400,000 were accumulated by Farallon Capital Mngmt Ltd Liability Corporation. Franklin Resources stated it has 775,886 shares or 0.01% of all its holdings. Parametric Port Assoc Ltd Limited Liability Company reported 0% in Immunomedics, Inc. (NASDAQ:IMMU). The Connecticut-based Massmutual Trust Fsb Adv has invested 0% in Immunomedics, Inc. (NASDAQ:IMMU). Vantage Investment Advsr Ltd Limited Liability Company holds 0% in Immunomedics, Inc. (NASDAQ:IMMU) or 248 shares. Spectrum Mgmt owns 1,250 shares. Lpl Ltd Liability Com owns 0% invested in Immunomedics, Inc. (NASDAQ:IMMU) for 12,451 shares. Jpmorgan Chase has 0% invested in Immunomedics, Inc. (NASDAQ:IMMU) for 34,214 shares. First Light Asset Management Limited Liability Company holds 4.27% or 1.16M shares in its portfolio.

Since June 15, 2018, it had 2 insider buys, and 0 sales for $18.48 million activity.

Ghost Tree Capital Llc decreased its stake in Immunomedics Inc (IMMU) by 32.43% based on its latest 2018Q2 regulatory filing with the SEC. Ghost Tree Capital Llc sold 600,000 shares as the company’s stock declined 0.90% while stock markets rallied. The hedge fund held 1.25M shares of the health care company at the end of 2018Q2, valued at $29.59M, down from 1.85M at the end of the previous reported quarter. Ghost Tree Capital Llc who had been investing in Immunomedics Inc for a number of months, seems to be less bullish one the $3.34B market cap company. The stock decreased 7.43% or $1.41 during the last trading session, reaching $17.57. About 2.31M shares traded or 19.64% up from the average. Immunomedics, Inc. (NASDAQ:IMMU) has risen 107.13% since December 8, 2017 and is uptrending. It has outperformed by 91.51% the S&P500.

Ghost Tree Capital Llc, which manages about $339.79 million US Long portfolio, upped its stake in Mersana Therapeutics Inc by 321,756 shares to 600,000 shares, valued at $10.72M in 2018Q2, according to the filing.

Analysts await Immunomedics, Inc. (NASDAQ:IMMU) to report earnings on February, 14. They expect $-0.31 earnings per share, down 63.16 % or $0.12 from last year’s $-0.19 per share. After $-0.35 actual earnings per share reported by Immunomedics, Inc. for the previous quarter, Wall Street now forecasts -11.43 % EPS growth.

More notable recent Immunomedics, Inc. (NASDAQ:IMMU) news were published by: Seekingalpha.com which released: “Immunomedics: Highly Investible Ahead Of PDUFA – Seeking Alpha” on November 27, 2018, also Fool.com with their article: “Here’s Why Immunomedics Fell as Much as 10.8% Today – Motley Fool” published on November 08, 2018, Nasdaq.com published: “Immunomedics Provides Clinical Updates on Breast Cancer Programs With Sacituzumab Govitecan – Nasdaq” on December 06, 2018. More interesting news about Immunomedics, Inc. (NASDAQ:IMMU) were released by: Seekingalpha.com and their article: “Hold On To Harsco – Cramer’s Lightning Round (12/3/18) – Seeking Alpha” published on December 04, 2018 as well as Nasdaq.com‘s news article titled: “IMMU Crosses Below Key Moving Average Level – Nasdaq” with publication date: November 12, 2018.

Immunomedics, Inc. (NASDAQ:IMMU) Ratings Coverage

Among 5 analysts covering Immunomedics (NASDAQ:IMMU), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Immunomedics had 5 analyst reports since August 24, 2018 according to SRatingsIntel. The firm has “Buy” rating given on Friday, August 24 by FBR Capital. The rating was reinitiated by Jefferies with “Buy” on Thursday, November 8.

Immunomedics, Inc. (NASDAQ:IMMU) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.